RG6353 / Roche - LARVOL DELTA

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Hoffmann-La Roche | Phase classification: P1/2 ➔ P1

Metastases • Phase classification • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • HLA-G • MUC16

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov) - P1/2 | N=3 | Terminated | Sponsor: Hoffmann-La Roche | N=150 ➔ 3 | Trial completion date: Jan 2027 ➔ Mar 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jan 2027 ➔ Mar 2024; Sponsor decision (not related to safety, efficacy or quality).

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • HLA-G • MUC16

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov) - P1/2 | N=150 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • HLA-G • MUC16

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor

HLA-G-TCB (RG6353), a T cell bispecific antibody for the treatment of solid tumors in monotherapy and combination with immunomodulator agents (AACR 2023) - "HLA-G is expressed in a broad range of solid tumor indications and its role in mediating immune suppression makes it an attractive cancer immunotherapy target.Anti-tumor activity of HLA-G-TCB was demonstrated in vitro using different HLA G positive tumor cell lines. T-cell activation, IFN"

Immunomodulating • Monotherapy • Oncology • Solid Tumor

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: Hoffmann-La Roche | Phase classification: P1 ➔ P1/2

Metastases • Phase classification • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Hoffmann-La Roche

Metastases • New P1 trial • Clear Cell Renal Cell Carcinoma • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor